Skip to main content
SpringerLink
Log in
Book cover

Precision Molecular Pathology of Bladder Cancer pp 117–136Cite as

Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood

  • Chapter
  • First Online:

  • 934 Accesses

Part of the book series: Molecular Pathology Library ((MPLB))

Abstract

Biomarkers can serve diagnostic, prognostic, or predictive roles. Application of biomarkers to bladder cancer involves the use of tissue obtained by interventional procedures, cytologic preparations obtained through bladder washes, collections of voided urine, and blood specimens. Different biomarkers may be more amenable for use in different preparations. Use of biomarkers to identify bladder cancers that are more likely to behave aggressively and potentially metastasize may help improve prognosis and treatment decisions. The use of biomarkers to predict response to specific therapies may help stratify which patients are enrolled into clinical trials or who receive targeted agents. Finally, biomarkers that can improve the ability to sub-stratify disease grade and stage can enhance our accuracy in diagnosis. Robust discovery of biomarkers in bladder cancer has been ongoing. However, the translation of these discoveries into clinical biomarker applications is more challenging. We will review different categories of biomarkers that are relevant for bladder cancer diagnosis, prognosis and prediction, with special emphasis on molecular biomarkers.

This is a preview of subscription content, log in via an institution.

References

  1. Czerniak B, Dinney C, McConkey D. Origins of bladder cancer. Annu Rev Pathol. 2016;11:149–74.

    Article  CAS  PubMed  Google Scholar 

  2. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010;28(4):429–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

    Article  CAS  Google Scholar 

  4. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Therap. 2010;10(5):407–15.

    Article  CAS  Google Scholar 

  5. Youssef RF, Lotan Y. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. Sci World J. 2011;11:369–81.

    Article  Google Scholar 

  6. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24):3967–72.

    Article  PubMed  Google Scholar 

  7. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176(4 Pt 1):1354–61. discussion 1361–1352

    Article  PubMed  Google Scholar 

  8. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010;28(4):389–400.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 1999;18(5):1197–203.

    Article  CAS  PubMed  Google Scholar 

  10. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22(6):1007–13.

    Article  CAS  PubMed  Google Scholar 

  11. Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163(12):922–31.

    Article  PubMed  Google Scholar 

  12. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331(19):1259–64.

    Article  CAS  PubMed  Google Scholar 

  13. Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4(4):829–34.

    CAS  PubMed  Google Scholar 

  14. Shariat SF, Chromecki TF, Cha EK, et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol. 2012;187(2):457–62.

    Article  PubMed  Google Scholar 

  15. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58(6):1090–4.

    CAS  PubMed  Google Scholar 

  16. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–24.

    Article  CAS  PubMed  Google Scholar 

  17. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst. 1992;84(16):1251–6.

    Article  CAS  PubMed  Google Scholar 

  18. Tokunaga H, Shariat SF, Green AE, et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001;51(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  19. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90(14):1072–9.

    Article  CAS  PubMed  Google Scholar 

  20. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  21. Barbieri CE, Lotan Y, Lee RK, et al. Tissue-based molecular markers for bladder cancer. Italian J Urol Nephrol. 2010;62(3):241–58.

    CAS  Google Scholar 

  22. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68–75.

    Article  PubMed  Google Scholar 

  23. Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29(25):3443–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lotan Y, Bagrodia A, Passoni N, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol. 2013;64(3):465–71.

    Article  CAS  PubMed  Google Scholar 

  25. Shariat SF, Passoni N, Bagrodia A, et al. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int. 2014;113(1):70–6.

    Article  PubMed  Google Scholar 

  26. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol. 2007;25(6):468–75.

    Article  CAS  PubMed  Google Scholar 

  27. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer. 2004;100(11):2367–75.

    Article  CAS  PubMed  Google Scholar 

  28. Levidou G, Saetta AA, Karlou M, et al. D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol. 2010;136(10):1563–71.

    Article  CAS  PubMed  Google Scholar 

  29. Lebret T, Becette V, Herve JM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol. 2000;37(6):654–9.

    Article  CAS  PubMed  Google Scholar 

  30. Pich A, Chiusa L, Formiconi A, et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer. 2002;95(4):784–90.

    Article  PubMed  Google Scholar 

  31. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114–9.

    Article  PubMed  Google Scholar 

  32. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369–73.

    Article  CAS  PubMed  Google Scholar 

  33. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17(9):2941–53.

    Article  CAS  PubMed  Google Scholar 

  34. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132–6.

    Article  CAS  PubMed  Google Scholar 

  35. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.

    Article  CAS  PubMed  Google Scholar 

  36. Shariat SF, Karakiewicz PI, Godoy G, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15(22):7012–9.

    Article  CAS  PubMed  Google Scholar 

  37. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70(3):482–6.

    Article  PubMed  Google Scholar 

  38. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109(6):1106–13.

    Article  CAS  PubMed  Google Scholar 

  39. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128–36.

    Article  CAS  PubMed  Google Scholar 

  40. Sakano S, Ogawa S, Yamamoto Y, et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol. 2013;1(3):403–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Klatte T, Seitz C, Rink M, et al. ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy. J Urol. 2015;194(5):1456–62.

    Article  CAS  PubMed  Google Scholar 

  43. Arcangeli G, Arcangeli S, Strigari L. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol. 2015;94(1):105–15.

    Article  PubMed  Google Scholar 

  44. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010;70(18):7017–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Teo MT, Dyrskjot L, Nsengimana J, et al. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol. 2014;25(4):877–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011;22(1):139–44.

    Article  CAS  PubMed  Google Scholar 

  47. Mullane SA, Werner L, Guancial EA, et al. Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma. Clin Genitourin Cancer. 2015;14(4):352–9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res. 2002;22(6a):3383–8.

    CAS  PubMed  Google Scholar 

  49. Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012;180(5):1824–34.

    Article  CAS  PubMed  Google Scholar 

  50. Schultz L, Albadine R, Hicks J, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. 2010;116(23):5517–26.

    Article  PubMed  Google Scholar 

  51. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010;12(8):628–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522–8.

    Article  CAS  PubMed  Google Scholar 

  53. Schneider SA, Sukov WR, Frank I, et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014;27(5):758–64.

    Article  CAS  PubMed  Google Scholar 

  54. Ching CB, Amin MB, Tubbs RR, et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol. 2011;24(8):1111–9.

    Article  CAS  PubMed  Google Scholar 

  55. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Curr Opin Oncol. 2015;27(3):191–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82.

    Article  CAS  PubMed  Google Scholar 

  58. Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–7.

    Article  CAS  PubMed  Google Scholar 

  59. Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015;85(3):703.e701–6.

    Article  Google Scholar 

  60. Friedrich MG, Toma MI, Petri S, Huland H. Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence. BJU Int. 2003;92(4):389–92.

    Article  CAS  PubMed  Google Scholar 

  61. Aziz A, Lessard A, Moore K, et al. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int. 2011;108(4):531–7.

    Article  CAS  PubMed  Google Scholar 

  62. Ke HL, HP T, Lin HH, et al. Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res. 2012;32(9):4111–6.

    PubMed  Google Scholar 

  63. Kang CH, Chiang PH, Huang SC. Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts. Urology. 2008;72(1):153–7.

    Article  PubMed  Google Scholar 

  64. Mokos I, Jakic-Razumovic J, Marekovic Z, Pasini J. Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer. Tumori. 2006;92(2):124–9.

    PubMed  Google Scholar 

  65. Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 2012;30(2):161–6.

    Article  CAS  PubMed  Google Scholar 

  66. Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001;57(1):60–5.

    Article  CAS  PubMed  Google Scholar 

  67. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 2011;12(2):137–43.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Marrone M, Potosky AL, Penson D, Freedman AN. A 22 gene-expression assay, decipher(R) (genomeDx biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy. PLoS Curr. 2015;7

    Google Scholar 

  69. Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015;67(1):165–70.

    Article  PubMed  Google Scholar 

  70. Culp SH, Dickstein RJ, Grossman HB, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014;191(1):40–7.

    Article  PubMed  Google Scholar 

  71. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  CAS  PubMed  Google Scholar 

  72. Jordan EJ, Iyer G. Targeted therapy in advanced bladder cancer: what have we learned? Urol Clin N Am. 2015;42(2):253–62. ix

    Article  Google Scholar 

  73. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007;104(32):13086–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Jones RT, Felsenstein KM, Theodorescu D. Pharmacogenomics: biomarker-directed therapy for bladder cancer. Urol Clin N Am. 2016;43(1):77–86.

    Article  Google Scholar 

  75. Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810–7.

    Article  CAS  PubMed  Google Scholar 

  76. Lin CT, Tung CL, Tsai YS, et al. Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. Urol Oncol. 2012;30(5):680–7.

    Article  PubMed  Google Scholar 

  77. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012;79(5):1085–91.

    Article  PubMed  Google Scholar 

  78. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK. Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol. 2013;27(8):1046–50.

    Article  PubMed  Google Scholar 

  79. Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol. 2014;66(6):1078–91.

    Article  CAS  PubMed  Google Scholar 

  80. Aziz A, Rink M, Gakis G, et al. Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int. 2014;93(3):352–60.

    Article  CAS  PubMed  Google Scholar 

  81. Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985–92.

    Article  CAS  PubMed  Google Scholar 

  82. Castillejo A, Rothman N, Murta-Nascimento C, et al. TGFB1 And TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer. 2009;124(3):608–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Shariat SF, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003;61(2):359–64.

    Article  PubMed  Google Scholar 

  84. Svatek RS, Shah JB, Xing J, et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010;116(19):4513–9.

    Article  CAS  PubMed  Google Scholar 

  85. Szarvas T, Becker M, vom Dorp F, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010;101(5):1300–8.

    Article  CAS  PubMed  Google Scholar 

  86. Matsumoto K, Ikeda M, Matsumoto T, et al. Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev. 2014;15(22):9927–31.

    Article  PubMed  Google Scholar 

  87. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007;13(7):2046–53.

    Article  CAS  PubMed  Google Scholar 

  88. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23(13):2903–10.

    Article  CAS  PubMed  Google Scholar 

  89. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182(3):907–13.

    Article  PubMed  Google Scholar 

  90. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78–84. discussion 84

    Article  PubMed  Google Scholar 

  91. Wang LC, Xylinas E, Kent MT, et al. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urol Oncol. 2014;32(4):433–40.

    Article  CAS  PubMed  Google Scholar 

  92. Yamana K, Bilim V, Hara N, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer. 2005;93(5):544–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Gunes S, Sullu Y, Yegin Z, Buyukalpelli R, Tomak L, Bagci H. ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma. Pathol Res Pract. 2013;209(2):99–104.

    Article  CAS  PubMed  Google Scholar 

  94. Korkolopoulou P, Levidou G, Trigka EA, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int. 2012;110(11 Pt C):E1237–48.

    Article  CAS  PubMed  Google Scholar 

  95. van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–41.

    Article  PubMed  Google Scholar 

  96. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87(21):1603–12.

    Article  CAS  PubMed  Google Scholar 

  97. Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res. 2006;12(3 Pt 1):800–6.

    Article  CAS  PubMed  Google Scholar 

  98. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010;70(5):1753–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd. J8.122, Dallas, TX, 75390-9110, USA

    Ryan Hutchinson & Yair Lotan

Authors
  1. Ryan Hutchinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yair Lotan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yair Lotan .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of California San Diego, San Diego, California, USA

    Donna E. Hansel

  2. Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA

    Seth P. Lerner

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Hutchinson, R., Lotan, Y. (2018). Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood. In: Hansel, D., Lerner, S. (eds) Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-64769-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64769-2_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64767-8

  • Online ISBN: 978-3-319-64769-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation